Diamyd Medical publishes the Annual Report for 2008/2009


Diamyd Medical's Annual Report for 2008/2009 is from today available in Swedish 
on the company website, www.diamyd.com.                                         

A printed Annual Report can be ordered by mail to Diamyd Medical, Linnégatan 89 
B, SE-115 23 Stockholm, or by e-mail to investor.relations@diamyd.com.          

Diamyd Medical's Annual General Meeting takes place on Friday December 11, 2009 
at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg        
auditorium) in Stockholm.                                                       

The English translation of the Annual Report will be available in approximately 
two weeks.                                                                      


For more information, please contact:                                           
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)                  
Phone: +46 8 661 0026                                                           

For pictures and press material, please contact:                                
Andreas Ericsson, Diamyd Medical AB (publ.)                                     
andreas.ericsson@diamyd.com                                                     
Phone: +46 8 661 0026                                                           


About Diamyd Medical                                                            
Diamyd Medical is a Swedish diabetes company focusing on the development of     
pharmaceuticals for the treatment of autoimmune diabetes and its complications. 
The company's most advanced project is the GAD-based drug Diamyd® for type 1    
diabetes. Phase III trials for this drug are in progress in both Europe and the 
US. In addition, the company has initiated clinical studies in the US in the    
area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS).   
The company has also out-licensed the use of GAD for the treatment of           
Parkinson's disease. The company currently has three clinical-phase products.   

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq 
OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)        
administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).     
Further information is available on the company's website: www.diamyd.com.      

This information is disclosed in accordance with the Swedish Securities Markets 
Act, the Swedish Financial Instruments Trading Act, or the requirements stated  
in the listing agreements.                                                      

Diamyd Medical AB (publ.)                                                       
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46   
(0)8 661 63 68                                                                  
E-mail: info@diamyd.com. VAT no: SE556530-142001.

Attachments

pr_eng-091127.pdf
GlobeNewswire